Final answer:
The question seems to address pharmacokinetics and the optimization of dosing for drugs such as Amodiaquine/sulfadoxine/pyrimethamine combinations. Adjusting for factors like patient mass and organ function is essential for efficacy and safety. The Kirby-Bauer assay is a laboratory method used to predict the effectiveness of antibiotics in treating patient infections.
Step-by-step explanation:
The question refers to steps within a systemic approach to drug information, possibly involving the optimization of therapy with existing drugs like Amodiaquine/sulfadoxine/pyrimethamine (combinations) and Artesunate/sulfadoxine/pyrimethamine. However, the specific 'AHS drug info systemic approach steps' were not provided, therefore a general response based on pharmacokinetics/pharmacodynamics will be discussed.Primarily, the dosage and route of administration are critical in ensuring that therapeutic drug levels are achieved without significant toxicity. For optimizing dosing, considerations like the patient's mass (especially in children), organ function, and potential side effects are paramount. Furthermore, to study the behavior of new chemical entities in the early drug development phase, major in vitro model systems are used to understand absorption, distribution, and metabolism.In terms of assessing the effectiveness of antimicrobials, a Kirby-Bauer assay can help predict therapeutic effectiveness by measuring the susceptibility of bacteria to antibiotics. The zone of inhibition (clear area around the antibiotic disk) reflects the drug's ability to halt bacterial growth, which can be correlated with potential in vivo success in a patient.